Leader in animal wellbeing solutions, Medical Ethics Pty Ltd, and animal nutrition provider, 4 Season Company, have established a new collaboration to trial pain mitigation technologies via a unique feed supplement.
The research and development studies will involve incorporating a pain relief agent that is similar to human over-the-counter anti-inflammatory drugs, into a specially formulated feed supplement based on a unique molasses mineral block technology.
Bayer through its Care4Cattle initiative has awarded one of its three prestigious global grants to Dr. Dominique van der Saag and the Sydney University Veterinarian Science Faculty. The grant will assist Medical Ethics and 4 Season Company to commence the first stage of the proof of concept studies.
Medical Ethics and 4 Season Company are working together to develop the technology that has the potential to deliver a range of pain mitigation therapies for livestock undergoing routine surgical procedures such as castration, disbudding, and to assist in the recovery from other painful ailments such as hoof abscesses. The technology also has the potential to help reduce pain and stress to cows during calving.
“Whilst the technology is still in the early stages this announcement was one of the company’s most significant animal wellbeing initiatives since the commercialisation of the Tri-Solfen pain mitigation technology. The awarding of the prestigious Bayer grant to our research partners Sydney University indicates the enormous potential the technology has to improve animal wellbeing outcomes globally.
“Currently there are no products providing pain relief in a simple, accessible form for animals to self-medicate. The combination of the Tri-Solfen technology (protected by 35 patents globally) and the introduction of the pain mitigated infused feed supplement has the potential to provide a practical, cost efficient and highly effective pain mitigation combination.
“This latest initiative is an important addition to our growing research and development pipeline.”
“Bayer Australia is thrilled that Dr van der Saag has been awarded a Care4Cattle grant for this innovation in advancing the well-being of cattle. Coming in the wake of the recent approval of Tri-Solfen for the new claim in disbudding and dehorning in calves, this grant underlines Bayer’s commitment to support ethical and sustainable practices in Australia’s animal industries”
In May, Medical Ethics announced it was investing $5.3 million (AUD) in researching the use of its Tri-Solfen pain mitigation technology for treatment of wounds in humans. Since commercialisation, Tri-Solfen has treated over 80 million farm animals in Australia.
– Ends –
Allan Giffard, Managing Director, Medical Ethics
0419 362 286
Celia Moore, FTI Consulting
0432 344 069
About Medical Ethics Pty Ltd
Medical Ethics Pty Ltd is a commercial and development company focused on pain mitigation in wounds for humans and animals. Our vision is to develop and deliver our proprietary highly effective, safe, affordable and practical pain relief platform to prevent pain and minimise suffering associated with wounds in humans, livestock and companion animals. Medical Ethics is focused on the development of the Group’s patented technology initially for the treatment of chronic wounds such as diabetic leg ulcers. Animal Ethics, a wholly owned subsidiary of Medical Ethics, is the first, and currently the only, company globally to develop, launch and commercialise a topical pain and wound management product for use in livestock undergoing painful husbandry procedures.
For further information, please visit http://medicalethics.me
About 4 Seasons Company
For further information, please visit https://www.fourseasonco.com.au/
Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286
Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000